Table 1

Baseline demographic by study group (ITT population)*

Baseline characteristicsSaline placebo
(n=100)
Bupivacaine HCl
50 mg
(n=155)
HTX-011
60 mg/1.8 mg
(n=157)
Age (years)
 Mean (SD)47.3 (12.83)45.5 (14.79)48.0 (14.47)
 Min, max19, 7718, 7718, 77
Sex, n (%)
 Female86 (86.0)132 (85.2)138 (87.9)
 Male14 (14.0)23 (14.8)19 (12.1)
Race, n (%)
 American Indian or Alaskan Native02 (1.3)1 (0.6)
 Asian2 (2.0)1 (0.6)8 (5.1)
 Black or African descent12 (12.0)22 (14.2)24 (15.3)
 Native Hawaiian or another Pacific Islander01 (0.6)0
 White86 (86.0)128 (82.6)123 (78.3)
 Multiple01 (0.6)1 (0.6)
Ethnicity, n (%)
 Hispanic or Latino32 (32.0)49 (31.6)47 (29.9)
 Not Hispanic or Latino68 (68.0)106 (68.4)110 (70.1)
Body mass index (kg/m2)
 Mean (SD)27.9 (5.05)27.2 (4.38)27.3 (4.79)
 Median27.326.726.8
 Min, max17.5, 38.417.3, 38.518.3, 38.6
  • *ITT population includes all subjects who were randomized and received study drug.

  • HCl, hydrochloride;ITT, intent to treat.